Foresite Capital Management VI’s Centessa Pharmaceuticals CNTA Stock Holding History

Foresite Capital Management VI’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,364,019	Closed	-$54.2M	–	24
2026 Q1	$54.2M	Hold	1,364,019	–	–	11.77%	3
2025 Q4	$34.1M	Buy	1,364,019 +50,000	+4%	+$1.27M	10.31%	4
2025 Q3	$31.9M	Buy	1,314,019 +60,640	+5%	+$1.08M	12.31%	3
2025 Q2	$16.5M	Hold	1,253,379	–	–	9.26%	2
2025 Q1	$18M	Hold	1,253,379	–	–	9.87%	3
2024 Q4	$21M	Buy	+1,253,379	New	+$20.8M	9.35%	3

Foresite Capital Management VI's CNTA Position: Q2 2026 in Review

Foresite Capital Management VI sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,364,019 shares — an estimated $54.2M sold.

Foresite Capital Management VI first reported a position in CNTA in Q4 2024 and held it in 6 quarters. The position peaked at $54.2M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Foresite Capital Management VI reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Foresite Capital Management VI sold 1,364,019 Centessa Pharmaceuticals shares in Q2 2026, an estimated $54.2M.
Foresite Capital Management VI first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Foresite Capital Management VI's Centessa Pharmaceuticals position peaked at $54.2M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.